CCRT with cetuximab group (n = 62) | CCRT group (n = 124) | P value | |
---|---|---|---|
Age, years | 1 | ||
Mean | 46.32 (25–64) | 46.05 (28–66) | |
Sex | 1 | ||
Male | 50 (80.6%) | 100 (80.6%) | |
Female | 12 (19.4%) | 24 (19.4%) | |
Pathological type | 1 | ||
WHO type II | 3 (4.8%) | 4 (3.2%) | |
WHO type III | 59 (95.2%) | 120 (96.8%) | |
T category | 1 | ||
T2 | 14 (22.6%) | 28 (22.6%) | |
T3 | 41 (66.1%) | 82 (66.1%) | |
T4 | 7 (11.3%) | 14 (11.3%) | |
N category | 1 | ||
N0 | 6 (9.7%) | 12 (9.7%) | |
N1 | 25 (40.3%) | 50 (40.3%) | |
N2 | 28 (45.2%) | 56 (45.2%) | |
N3 | 3 (4.8%) | 6 (4.8%) | |
Disease stage | 1 | ||
II | 5 (8.1%) | 10 (8.1%) | |
III | 47 (75.8%) | 94 (75.8%) | |
IVA | 7 (11.3%) | 14 (11.3%) | |
IVB | 3 (4.8%) | 6 (4.8%) | |
RT technique | 1 | ||
2DRT | 10 (16.1%) | 20 (16.1%) | |
IMRT | 52 (83.9%) | 104 (83.9% | |
Cisplatin delivery | 0.144 | ||
Every 3 weeks(80–100 mg/m2) | 39 (62.9%) | 64 (51.6%) | |
Weekly (30–40 mg/m2) | 23 (37.1%) | 60 (48.4%) | |
EBV DNA level | 1 | ||
< 4000 copies | 35 (56.5%) | 70 (56.5%) | |
≥ 4000 copies | 27 (43.5%) | 54 (43.5%) | |
VCA-IgA | 1 | ||
< 1:80 | 15 (24.2%) | 30 (24.2%) | |
≥ 1:80 | 47 (75.8%) | 94 (75.8%) | |
EA-IgA | 0.148 | ||
< 1:10 | 24 (38.7%) | 35 (28.2%) | |
≥ 1:10 | 38 (61.3%) | 89 (71.8%) | |
ECOG | 1 | ||
0 | 1 (1.6%) | 2 (1.6%) | |
1 | 61 (98.4%) | 122 (98.4%) | |
LDH,U/L | 0.666 | ||
< 245 | 61 (98.4%) | 120 (96.8%) | |
≥ 245 | 1 (1.6%) | 4 (3.2%) | |
CRP,g/ml | 0.286 | ||
< 3.00 | 49 (79.0%) | 89 (71.8%) | |
≥ 3.00 | 13 (21.0%) | 35 (28.2%) | |
Body mass index, kg/m2 | 1 | ||
< 18.5 | 3 (4.8%) | 5 (4.0%) | |
≥ 18.5 | 59 (95.2%) | 119 (96.0%) | |
Smoking | 0.46 | ||
Yes | 20 (32.2%) | 59 (47.6%) | |
No | 42 (67.7%) | 65 (52.4%) | |
Family history of cancer | 0.02 | ||
Yes | 13 (21.0%) | 11 (8.9%) | |
No | 49 (79.0%) | 113 (91.1%) |